Experimental Treatment for Ewing’s Sarcoma Earns Rare Pediatric Disease Designation From the FDA
sasint / Pixabay

Experimental Treatment for Ewing’s Sarcoma Earns Rare Pediatric Disease Designation From the FDA

According to a story from BioSpace, the cancer drug company Gibson Oncology, LLC has recently announced that the US Food and Drug Administration (FDA) has awarded Rare Pediatric Disease designation…

Continue Reading Experimental Treatment for Ewing’s Sarcoma Earns Rare Pediatric Disease Designation From the FDA
Drug Developer Receives $900,000 for the Development of a Gene Therapy for Epidermolysis Bullosa
ColiN00B / Pixabay

Drug Developer Receives $900,000 for the Development of a Gene Therapy for Epidermolysis Bullosa

According to a story from pm360online.com, the gene therapy company Fibrocell Science, Inc., recently received an investment of $900,000 from the Epidermolysis Bullosa Medical Research Foundation (EBMRF) and the EB…

Continue Reading Drug Developer Receives $900,000 for the Development of a Gene Therapy for Epidermolysis Bullosa

Clinical Trial Results With Velcade in Mantle Cell Lymphoma Inspire Continued Research

According to a story from curetoday.com, a recent Phase 2 trial has demonstrated that bortezomib (marketed as Velcade) has the potential to be an effective therapy for patients with mantle…

Continue Reading Clinical Trial Results With Velcade in Mantle Cell Lymphoma Inspire Continued Research